IL298148A - Sting agonist combination therapies with immune checkpoint inhibitors - Google Patents

Sting agonist combination therapies with immune checkpoint inhibitors

Info

Publication number
IL298148A
IL298148A IL298148A IL29814822A IL298148A IL 298148 A IL298148 A IL 298148A IL 298148 A IL298148 A IL 298148A IL 29814822 A IL29814822 A IL 29814822A IL 298148 A IL298148 A IL 298148A
Authority
IL
Israel
Prior art keywords
inhibitor
sting agonist
administered
ctla4
patient
Prior art date
Application number
IL298148A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immunesensor Therapeutics Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunesensor Therapeutics Inc, Univ Texas filed Critical Immunesensor Therapeutics Inc
Publication of IL298148A publication Critical patent/IL298148A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL298148A 2020-05-15 2021-05-17 Sting agonist combination therapies with immune checkpoint inhibitors IL298148A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025905P 2020-05-15 2020-05-15
US202063091874P 2020-10-14 2020-10-14
PCT/US2021/032800 WO2021232019A1 (en) 2020-05-15 2021-05-17 Sting agonist combination treatments with immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
IL298148A true IL298148A (en) 2023-01-01

Family

ID=76306053

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298148A IL298148A (en) 2020-05-15 2021-05-17 Sting agonist combination therapies with immune checkpoint inhibitors

Country Status (10)

Country Link
US (1) US20210380695A1 (cg-RX-API-DMAC10.html)
EP (1) EP4149457A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023533111A (cg-RX-API-DMAC10.html)
KR (1) KR20230011324A (cg-RX-API-DMAC10.html)
CN (1) CN115803032A (cg-RX-API-DMAC10.html)
AU (1) AU2021273508A1 (cg-RX-API-DMAC10.html)
CA (1) CA3178464A1 (cg-RX-API-DMAC10.html)
IL (1) IL298148A (cg-RX-API-DMAC10.html)
MX (1) MX2022014110A (cg-RX-API-DMAC10.html)
WO (1) WO2021232019A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940679B (zh) * 2022-05-23 2023-05-16 浙江大学医学院附属第四医院 Sting激动剂前药化合物及其制备方法和应用
WO2024064724A1 (en) * 2022-09-21 2024-03-28 The University Of North Carolina At Chapel Hill Compositions and methods for treating cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
EP4122492A1 (en) * 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
IL280430B2 (en) * 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3755331B1 (en) 2018-02-21 2026-01-28 The Scripps Research Institute Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
JP2023500045A (ja) * 2019-10-14 2023-01-04 イミューンセンサー セラピューティクス、インコーポレイテッド Stingアゴニストを用いたがんを処置する方法

Also Published As

Publication number Publication date
KR20230011324A (ko) 2023-01-20
MX2022014110A (es) 2023-01-30
EP4149457A1 (en) 2023-03-22
JP2023533111A (ja) 2023-08-02
US20210380695A1 (en) 2021-12-09
AU2021273508A1 (en) 2022-12-15
WO2021232019A1 (en) 2021-11-18
CA3178464A1 (en) 2021-11-18
CN115803032A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
Andrikopoulou et al. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer
Sigalov A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock
NZ551406A (en) Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)
IL247320B (en) Use of il -2r beta – selective agonists in combination with anti ctla – 4 or pd - 1 antibodies for treating cancer
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
IL298438A (en) Therapeutic combinations comprising anti-folr1 immunoconjugates
IL264267A (en) Radioactive substances that are converted to halogen for the immunization of a modulated cancer vaccine on site
KR20230169462A (ko) Liv1-adc와 체크포인트 억제제를 사용한 병용 요법
NZ551431A (en) Treatment with cisplatin and an EGFR-inhibitor
IL290857B (en) Oxabicycloheptanes for immune response modulation
Goldwasser et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients
Sharma et al. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
US20220401556A1 (en) Use of vdas to enhance immunomodulating therapies against tumors
KR20240130081A (ko) 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용
WO2021232019A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
US20230121320A1 (en) Sting agonist combination treatments with cytokines
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL298155A (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
US20230270773A1 (en) Methods of treating cancer with a sting agonist
CN115463217B (zh) 己酸羟孕酮在增强肿瘤治疗效果中的应用
JP2026503517A (ja) Nhl治療薬の製造における抗cd20抗体-薬物コンジュゲートを含む医薬組成物の使用
HK40087098A (en) Sting agonist combination treatments with immune checkpoint inhibitors
WO2018148555A1 (en) Use of vdas to enhance immunomodulating therapies against tumors
McLaughlin et al. Antibody–Drug Conjugates (ADCs) in clinical development
KR20260057087A (ko) Steap1xcd3에 결합하는 이중특이적 항체를 이용하여 전립선암을 치료하는 방법